Pharmacotherapy for treatment-resistant schizophrenia

References

• SahaSChantDWelhamJMcGrathJA systematic review of the prevalence of schizophreniaPLoS Med200525e14115916472
   PubMed Web of Science ®Google Scholar
• MarderSRInitiatives to promote the discovery of drugs to improve cognitive function in severe mental illnessJ Clin Psychiatry2006677e0317107228
   PubMedGoogle Scholar
• GurejeOHerrmanHHarveyCMorganVJablenskyAThe Australian national survey of psychotic disorders: Profile of psychosocial disability and its risk factorsPsychol Med200232463964712102378
   PubMed Web of Science ®Google Scholar
• JablenskyAMcGrathJHerrmanHCastleDGurejeOEvansMPsychotic disorders in urban areas: An overview of the study on low prevalence disordersAust N Z J Psychiatry200034222123610789527
   PubMed Web of Science ®Google Scholar
• ThornicroftGTansellaMBeckerTKnappMLeeseMScheneAThe personal impact of schizophrenia in europeSchizophr Res2004692–312513215469185
   PubMed Web of Science ®Google Scholar
• WheelerASociodemographic, functional and clinical correlates in outpatients with schizophrenia: Comparison with affective disordersAust N Z J Psychiatry2007411080981817828654
   PubMed Web of Science ®Google Scholar
• StroupTSLiebermanJAMcEvoyJPDavisSMSwartzMSKeefeRSResults of phase 3 of the catie schizophrenia trialSchizophr Res2009107111219027269
   PubMed Web of Science ®Google Scholar
• JonesPBBarnesTRDaviesLDunnGLloydHHayhurstKPRandomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (cutlass 1)Arch Gen Psychiatry200663101079108717015810
   PubMed Web of Science ®Google Scholar
• LehmanALJDixonLAPA practice guidelines: SchizophreniaAm J Psychiatry2004161Suppl 215615000267
   PubMed Web of Science ®Google Scholar
• CarpenterWJrHeinrichsDWagmanADeficit and nondeficit forms of schizophrenia: The conceptAm J Psychiatry198814555785833358462
   PubMed Web of Science ®Google Scholar
• ErhartSMMarderSRCarpenterWTTreatment of schizophrenia negative symptoms: Future prospectsSchizophr Bull32223423716492797
   PubMed Web of Science ®Google Scholar
• StahlSMBuckleyPFNegative symptoms of schizophrenia: A problem that will not go awayActa Psychiatr Scand2007115141117201860
   PubMed Web of Science ®Google Scholar
• KirkpatrickBFentonWSCarpenterWTMarderSRThe nimhmatrics consensus statement on negative symptomsSchizophr Bull200632221421916481659
   PubMed Web of Science ®Google Scholar
• BreierASchreiberJLDyerJPickarDNational institute of mental health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcomeArch Gen Psychiatry19914832392461671741
   PubMed Web of Science ®Google Scholar
• TandonRRibeiroSCMDeQuardoJRGoldmanRSGoodsonJGredenJFCovariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replicationBiol Psychiatry19933474954977903556
   PubMed Web of Science ®Google Scholar
• HarveyPDKeefeRSEStudies of cognitive change in patients with schizophrenia following novel antipsychotic treatmentAm J Psychiatry2001158217618411156796
   PubMed Web of Science ®Google Scholar
• MisharaALGoldbergTEA meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed bookBiol Psychiatry200455101013102215121486
   PubMed Web of Science ®Google Scholar
• MortimerAMCognitive function in schizophrenia – do neuroleptics make a difference?Pharmacol Biochem Behav19975647897959130306
   PubMed Web of Science ®Google Scholar
• BilderRMNeurocognitive impairment in schizophrenia and how it affects treatment optionsCan J Psychiatry19974232552649114941
   PubMed Web of Science ®Google Scholar
• GreenMFBraffDLTranslating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medicationsBiol Psychiatry200149437438411239909
   PubMed Web of Science ®Google Scholar
• TandonRNasrallahHAKeshavanMSSchizophrenia, “just the facts” 5. Treatment and prevention past, present, and futureSchizophr Res20101221–312320655178
   PubMed Web of Science ®Google Scholar
• GoldbergTEGoldmanRSBurdickKEMalhotraAKLenczTPatelRCCognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect?Arch Gen Psychiatry200764101115112217909123
   PubMed Web of Science ®Google Scholar
• DavidsonMGalderisiSWeiserMWerbeloffNFleischhackerWWKeefeRSCognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (eufest)Am J Psychiatry2009166667568219369319
   PubMed Web of Science ®Google Scholar
• HillSKBishopJRPalumboDSweeneyJAEffect of second-generation antipsychotics on cognition: Current issues and future challengesExpert Rev Neurother2009101435720021320
   PubMed Web of Science ®Google Scholar
• KeefeRSEBilderRMDavisSMHarveyPDPalmerBWGoldJMNeurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the catie trialArch Gen Psychiatry200764663364717548746
   PubMed Web of Science ®Google Scholar
• KaneJHonigfeldGSingerJMeltzerHClozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazineArch Gen Psychiatry19884597897963046553
   PubMed Web of Science ®Google Scholar
• KerwinRWBolonnaAManagement of clozapine-resistant schizophreniaAdvances in Psychiatric Treatment2005112101106
   Google Scholar
• ConleyRRKellyDLManagement of treatment resistance in schizophreniaBiol Psychiatry2001501189891111743944
   PubMed Web of Science ®Google Scholar
• BuckleyPFKrowinskiACMillerDDFriedmanLEatonYTronettiMClinical and biochemical correlates of ‘high-dose’ clozapine therapy for treatment – refractory schizophreniaSchizophr Res2001491–222522711428347
   PubMed Web of Science ®Google Scholar
• ChakosMLiebermanJHoffmanEBradfordDSheitmanBEffectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trialsAm J Psychiatry2001158451852611282684
   PubMed Web of Science ®Google Scholar
• TandonRBelmakerRHGattazWFLopez-IborJJJrOkashaASinghBWorld psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophreniaSchizophr Res20081001–3203818243663
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• EssaliAAl-Haj HaasanNLiCRathboneJClozapine versus typical neuroleptic medication for schizophreniaCochrane Database Syst Rev20091CD00005919160174
   PubMed Web of Science ®Google Scholar
• GeddesJFreemantleNHarrisonPBebbingtonPAtypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysisBMJ200032172731371137611099280
   PubMed Web of Science ®Google Scholar
• LeuchtSWahlbeckKHamannJKisslingWNew generation antipsychotics versus low-potency conventional antipsychotics: A systematic review and meta-analysisLancet200336193691581158912747876
   PubMed Web of Science ®Google Scholar
• RosenheckRAOpen forum: Effectiveness versus efficacy of second-generation antipsychotics: Haloperidol without anticholinergics as a comparatorPsychiatr Serv2005561859215637198
   PubMed Web of Science ®Google Scholar
• MeltzerHYBoboWVLeeMAColaPJayathilakeKA randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophreniaPsychiatry Res2010177328629320378185
   PubMed Web of Science ®Google Scholar
• KrakowskiMICzoborPNolanKAAtypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patientsJ Clin Psychopharmacol200828548549318794642
   PubMed Web of Science ®Google Scholar
• KrakowskiMCzoborPCitromeLWeight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidolSchizophr Res20091101–39510219269139
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCCorvesCHungerHSchmidFA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• RosenheckRCramerJXuWThomasJHendersonWFrismanLA comparison of clozapine and haloperidol in hospitalized patients with refractory schizophreniaN Engl J Med1997337128098159295240
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSHungerHSchmidFLobosCAHead-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysisSchizophr Res201012322523320692814
   PubMed Web of Science ®Google Scholar
• McEvoyJPLiebermanJAStroupTSDavisSMMeltzerHYRosenheckRAEffectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatmentAm J Psychiatry2006163460061016585434
   PubMed Web of Science ®Google Scholar
• ChengappaKNPollockBGParepallyHLevineJKirshnerMABrarJSAnticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapineJ Clin Psychopharmacol200020331131610831017
   PubMed Web of Science ®Google Scholar
• EngelbergHLow serum cholesterol and suicideLancet199233987957277291347593
   PubMed Web of Science ®Google Scholar
• KrakowskiMICzoborPA prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine, and haloperidolJ Clin Psychopharmacol201030219820020520296
   PubMed Web of Science ®Google Scholar
• LewisSWBarnesTRDaviesLMurrayRMDunnGHayhurstKPRandomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophreniaSchizophr Bull200632471572316540702
   PubMed Web of Science ®Google Scholar
• CohenLJTestMABrownRLSuicide and schizophrenia: Data from a prospective community treatment studyAm J Psychiatry199014756026072327487
   PubMed Web of Science ®Google Scholar
• MeltzerHYAlphsLGreenAIAltamuraACAnandRBertoldiAClozapine treatment for suicidality in schizophrenia: International suicide prevention trial (intersept)Arch Gen Psychiatry2003601829112511175
   PubMed Web of Science ®Google Scholar
• HarveyPDSacchettiEGalluzzoARomeoFGoriniBBilderRMA randomized double-blind comparison of ziprasidone vs clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatmentSchizophr Res20081051–313814318077136
   PubMed Web of Science ®Google Scholar
• DaviesLMBarnesTRJonesPBLewisSGaughranFHayhurstKA randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapineValue Health200811454956218179662
   PubMed Web of Science ®Google Scholar
• KumraSKranzlerHGerbino-RosenGKesterHMDe ThomasCKafantarisVClozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparisonBiol Psychiatry200863552452917651705
   PubMed Web of Science ®Google Scholar
• MeltzerHYBoboWVRoyAJayathilakeKChenYErtugrulAA randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophreniaJ Clin Psychiatry200869227428518232726
   PubMed Web of Science ®Google Scholar
• SacchettiEGalluzzoAValsecchiPRomeoFGoriniBWarringtonLZiprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The mozart studySchizophr Res200911311122119606529
   PubMed Web of Science ®Google Scholar
• MouaffakFTranulisCGourevitchRPoirierMFDoukiSOlieJPAugmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophreniaClin Neuropharmacol200629283316518132
   PubMed Web of Science ®Google Scholar
• BarbuiCSignorettiAMuleSBosoMCiprianiADoes the addition of a second antipsychotic drug improve clozapine treatment?Schizophr Bull200935245846818436527
   PubMed Web of Science ®Google Scholar
• CiprianiABosoMBarbuiCClozapine combined with different antipsychotic drugs for treatment resistant schizophreniaCochrane Database Syst Rev20093CD00632419588385
   PubMed Web of Science ®Google Scholar
• CorrellCURummel-KlugeCCorvesCKaneJMLeuchtSAntipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trialsSchizophr Bull200935244345718417466
   PubMed Web of Science ®Google Scholar
• TaylorDMSmithLAugmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studiesActa Psychiatr Scand2009119641942519245679
   PubMed Web of Science ®Google Scholar
• GoffDCCoyleJTThe emerging role of glutamate in the pathophysiology and treatment of schizophreniaAm J Psychiatry200115891367137711532718
   PubMed Web of Science ®Google Scholar
• CunninghamMOJonesRSGThe anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous gaba release in the rat entorhinal cortex in vitroNeuropharmacology200039112139214610963757
   PubMed Web of Science ®Google Scholar
• LeachMJBaxterMGCritchleyMANeurochemical and behavioural aspects of lamotrigineEpilepsia199132Suppl 2S4S81685439
   PubMed Web of Science ®Google Scholar
• TiihonenJWahlbeckKKiviniemiVThe efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysisSchizophr Res20091091–3101419186030
   PubMed Web of Science ®Google Scholar
• GreenMFWhat are the functional consequences of neurocognitive deficits in schizophrenia?Am J Psychiatry199615333213308610818
   PubMed Web of Science ®Google Scholar
• KrystalJHKarperLPSeibylJPFreemanGKDelaneyRBremnerJDSubanesthetic effects of the noncompetitive nmda antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responsesArch Gen Psychiatry19945131992148122957
   PubMed Web of Science ®Google Scholar
• MalhotraAKPinalsDAAdlerCMElmanICliftonAPickarDKetamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenicsNeuropsychopharmacology19971731411509272481
   PubMed Web of Science ®Google Scholar
• LahtiACHolcombHHMedoffDRTammingaCAKetamine activates psychosis and alters limbic blood flow in schizophreniaNeuroreport1995668698727612873
   PubMed Web of Science ®Google Scholar
• TsaiGELinPYStrategies to enhance n-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysisCurr Pharm Des201016552253719909229
   PubMed Web of Science ®Google Scholar
• WhiteHSBrownSDWoodheadJHSkeenGAWolfHHTopiramate enhances gaba-mediated chloride flux and gaba-evoked chloride currents in murine brain neurons and increases seizure thresholdEpilepsy Research19972831671799332882
   PubMed Web of Science ®Google Scholar
• GibbsJWSombatiSDeLorenzoRJCoulterDACellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neuronsEpilepsia200041Suppl 1S10S1610768293
   PubMed Web of Science ®Google Scholar
• ÄngehagenMShankRHanssonERönnbäckLBen-MenachemETopiramate affects the ability of protein kinase to phosphorylate glutamate receptors activated by kainateEpilepsia200142Suppl 7S10
   Google Scholar
• ArnoneDReview of the use of topiramate for treatment of psychiatric disordersAnn Gen Psychiatry200541515845141
   PubMedGoogle Scholar
• ShankRPGardockiJFStreeterAJMaryanoffBEAn overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of actionEpilepsia200041Suppl 1S3S910768292
   PubMed Web of Science ®Google Scholar
• AfsharHRoohafzaHMousaviGGolchinSToghianifarNSadeghiMTopiramate add-on treatment in schizophrenia: A randomised, double-blind, placebo-controlled clinical trialJ Psychopharmacol200923215716218515465
   PubMed Web of Science ®Google Scholar
• ArifHBuchsbaumRWeintraubDPierroJResorSRJrHirschLJPatient-reported cognitive side effects of antiepileptic drugs: Predictors and comparison of all commonly used antiepileptic drugsEpilepsy Behav200914120220919010446
   PubMed Web of Science ®Google Scholar
• GilliamFGVelosoFBomhofMAGazdaSKBitonVTer BruggenJPA dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsyNeurology2003602196120212552030
   PubMed Web of Science ®Google Scholar
• LeeSSziklasVAndermannFFarnhamSRisseGGustafsonMThe effects of adjunctive topiramate on cognitive function in patients with epilepsyEpilepsia200344333934712614389
   PubMed Web of Science ®Google Scholar
• ThompsonPJBaxendaleSADuncanJSSanderJWEffects of topiramate on cognitive functionJ Neurol Neurosurg Psychiatry200069563664111032616
   PubMed Web of Science ®Google Scholar
• MuscatelloMRABrunoAPandolfoGMicòUBellinghieriPMScimecaGTopiramate augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled studyJ Psychopharmacology201078 [Epub ahead of print].
   Web of Science ®Google Scholar
• StreinerDLThe case of the missing data: Methods of dealing with dropouts and other research vagariesCan J Psychiatry2002471687511873711
   PubMed Web of Science ®Google Scholar
• AndreasenNCThe Scale for Assessment of Positive Symptoms (SAPS)Iowa City, IA1984 http://www.movementdisorders.org/UserFiles/file/Long_SAPS_2000_publish(1).pdf.
   Google Scholar
• DeutschSISchwartzBLRosseRBMastropaoloJMarvelCLDrapalskiALAdjuvant topiramate administration: A pharmacologic strategy for addressing nmda receptor hypofunction in schizophreniaClin Neuropharmacol200326419920612897641
   PubMed Web of Science ®Google Scholar
• De LucenaDFernandesBSBerkMDoddSMedeirosDWPedriniMImprovement of negative and positive symptoms in treatment-refractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapineJ Clin Psychiatry200970101416142319906345
   PubMed Web of Science ®Google Scholar
• LancuIOlmerAThe minimental state examination – an up-to-date reviewHarefuah2006145968769070117078433
   PubMedGoogle Scholar
• MeisnerFSchellerCKneitzSSopperSNeuen-JacobERiedererPMemantine upregulates bdnf and prevents dopamine deficits in siv-infected macaques: A novel pharmacological action of memantineNeuropsychopharmacology20083392228223617971830
   PubMed Web of Science ®Google Scholar
• PanWBanksWAFasoldMBBluthJKastinAJTransport of brain-derived neurotrophic factor across the blood-brain barrierNeuropharmacology19983712155315619886678
   PubMed Web of Science ®Google Scholar
• GamaCSAndreazzaACKunzMBerkMBelmonte-de-AbreuPSKapczinskiFSerum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorderNeurosci Lett20074201454817442489
   PubMed Web of Science ®Google Scholar
• LiebermanJAPapadakisKCsernanskyJLitmanRVolavkaJJiaXDA randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophreniaNeuropsychopharmacology20093451322132919005465
   PubMed Web of Science ®Google Scholar
• FreudenreichOHendersonDCMacklinEAEvinsAEFanXCatherCModafinil for clozapine-treated schizophrenia patients: A double-blind, placebo-controlled pilot trialJ Clin Psychiatry200970121674168019689921
   PubMed Web of Science ®Google Scholar
• GoffDCLambertiJSLeonACGreenMFMillerALPatelJA placebo-controlled add-on trial of the ampakine, cx516, for cognitive deficits in schizophreniaNeuropsychopharmacology200833346547217487227
   PubMed Web of Science ®Google Scholar
• TammingaCACarlssonAPartial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosisCurr Drug Targets CNS Neurol Disord20021214112769623
   PubMedGoogle Scholar
• Rivas-VasquezRAAripiprazole: A novel antipsychotic with dopamine stabilising propertiesProf Psychol Res Pr2003341108111
   Web of Science ®Google Scholar
• MillarHFelterCLandsbergWThe effects of aripiprazole in combination with clozapine: Patient functioning results from a double-blind, 16-week study in patients with schizophrenia (cn138-170)J Psychopharmacol2008225A17
   Google Scholar
• FleischhackerWWHeikkinenMEOlieJPLandsbergWDewaelePMcQuadeRDEffects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trialInt J Neuropsychopharmcol201013811151125
   PubMed Web of Science ®Google Scholar
• KumraSKranzlerHGerbino-RosenGKesterHMDeThomasCCullenKClozapine versus “high-dose” olanzapine in refractory early-onset schizophrenia: An open-label extension studyJ Child Adolesc Psychopharmacol200818430731618759640
   PubMed Web of Science ®Google Scholar
• BarrettoEMKayoMAvrichirBSSaARCamargoMGNapolitanoICA preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophreniaJ Nerv Ment Dis20091971186586819996727
   PubMed Web of Science ®Google Scholar
• TurkingtonDSenskyTScottJBarnesTRENurUSiddleRA randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: A five-year follow-upSchizophr Res2008981–31717936590
   PubMed Web of Science ®Google Scholar
• MathesonSLGreenMJLooCCarrVJQuality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial magnetic stimulation for schizophrenia: A systematic meta-reviewSchizophr Res20101181–320121020117918
   PubMed Web of Science ®Google Scholar
• BurtTLisanbySHSackeimHANeuropsychiatric applications of transcranial magnetic stimulation: A meta analysisInt J Neuropsychopharmacol2002517310312057034
   PubMed Web of Science ®Google Scholar
• TharyanPAdamsCEElectroconvulsive therapy for schizophreniaCochrane Database Syst Rev2005182CD00007615846598
   PubMedGoogle Scholar
• AlemanASommerIEKahnRSEfficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: A meta-analysisJ Clin Psychiatry200768341642117388712
   PubMed Web of Science ®Google Scholar
• Lévy-RueffMGourevitchRLôoHOliéJ-PAmadoIMaintenance electroconvulsive therapy: An alternative treatment for refractory schizophrenia and schizoaffective disordersPsychiatry Res2010175328028320034675
   PubMed Web of Science ®Google Scholar